ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United ...

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades 1 Second approval of ZORYVE outside of the United ...

Arcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical ...

Arcutis Biotherapeutics, Inc. ARQT announced that the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in ...

TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth ...

$20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth of 452% vs. Q3 '23 and 45% vs. Q2 '24 Continued gross-to-net (GTN) improvement with blended GTN across products ...

Zoryve foam for seborrheic dermatitis was approved in Canada one month ago. Arcutis Biotherapeutics posted its Q3 numbers on November 6th. The company delivered a GAAP loss of 33 cents a share ...